CAMP and glioblastoma: Since the combination of NE/CAMPs and aPD‐1 exhibited a potent anti‐tumor effect on GBM cells in vivo in the subcutaneous GL261 model, we investigated the potency of NE/CAMP+aPD‐1 combination therapy in an orthotopic GL261 GBM mouse model.